Role of exon 7 PTEN Gene in Endometrial Carcinoma

  • Kafshdooz, Leila (Women's Reproductive Health Research Center, Tabriz University of Medical Sciences) ;
  • Kafshdooz, Taiebeh (Women's Reproductive Health Research Center, Tabriz University of Medical Sciences) ;
  • Tabrizi, Ali Dastranj (Women's Reproductive Health Research Center, Tabriz University of Medical Sciences) ;
  • Ardabili, Seyyed Mojtaba Mohaddes (Faculty of Medicine, Tabriz University of Medical Sciences) ;
  • Akbarzadeh, Abolfazl (Department of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences) ;
  • Gharesouran, Jalal (Faculty of Medicine, Tabriz University of Medical Sciences) ;
  • Ghojazadeh, Morteza (Faculty of Medicine, Tabriz University of Medical Sciences) ;
  • Farajnia, Safar (Drug Applied Research Center, Tabriz University of Medical Sciences)
  • Published : 2015.06.26


Background: Endometrial carcinoma is the most common malignant tumor of the female genital tract and the fourth most common cancer in Iranian women after breast, colorectal and lung cancers. Various genetic alterations appear to be early events in the pathogenesis of endometrial carcinoma and it seems that PTEN is the most commonly mutated gene in the endometrioid subtype. The aim of the present study was to investigate the correlation between mutations in exon 7 of PTEN gene and endometrial carcinoma. Materials and Methods: Seventy-five patients with endometrial carcinoma and 75 females whose underwent hysterectomy for non tumoral indication were selected for evaluation of PTEN mutations in exon 7 by PCR-SSCP and sequencing. Correlations between the frequency and type of mutation and the pathologic findings of the cancer (tumor subtype, stage and grade) were assessed. Results: All of the samples were obtained from Iranian patients. 60 % (45 cases) of the tumors were endometriod and 40% (30 cases) were of serous type. The grade distributions of the 75 cases according to the FIGO staging system were as follows: low grade, 20 cases; high grade 55 cases, low stage, 41 cases; high stage 34 cases. For exon 7 of the PTEN gene, the analysis showed that there were no mutations in our cases. Conclusions: Our findings in the present study suggest that exon 7 of PTEN does not play any significant role in the development of endometrial carcinoma in Iranian cases.


Endometrial carcinoma;PTEN;exon 7;mutations


  1. Ali IU, Schriml LM, Dean M (1999). Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. JNCI J Natl Cancer Inst, 91, 1922-32.
  2. Ashton K, Proietto A, Otton G, et al (2009). Estrogen receptor polymorphisms and the risk of endometrial cancer. BJOG, 116, 1053-61.
  3. Balik G, Kagitci M, Ustuner I, et al (2013). Which endometrial pathologies need intraoperative frozen sections? Asian Pac J Cancer Prev, 14, 6121-5.
  4. Bansal N, Yendluri V, Wenham RM (2009). The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control J Moffitt Cancer Cente, 16, 8.
  5. Chalhoub N, Baker SJ (2009). PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol, 4, 127.
  6. Chow LM, Baker SJ (2006). PTEN function in normal and neoplastic growth. Cancer Lett, 241, 184-96.
  7. Fader AN, Arriba LN, Frasure HE, von Gruenigen VE (2009). Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol, 114, 121-7.
  8. Gadducci A, Cosio S, Genazzani AR (2011). Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer. Crit Rev Oncol Hematolv, 80, 181-92.
  9. Gericke A, Munson M, Ross AH (2006). Regulation of the PTEN phosphatase. Gene, 374, 1-9.
  10. Hernandez E, Obermair A, Hoskins PJ, Magrina JF, Mclellan R (2010). Controversies in the management of endometrial cancer. Obstet Gynecol Int. [Epub ahead of print].
  11. Jiang X-F, Tang Q-L, Zou Y, et al (2014). Does HBV infection increase risk of endometrial carcinoma? Asian Pac J Cancer Prev, 15, 713-6.
  12. Konopka B, Janiec-Jankowska A, Czapczak D, et al (2007). Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and beta-catenin (CTNNB1) genes mutations. J Cancer Res Clin Oncol, 133, 361-71.
  13. Lee J-O, Yang H, Georgescu M-M, et al (1999). Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell, 99, 323-34.
  14. Liu FS (2007). Molecular carcinogenesis of endometrial cancer. Taiwanese J Obstet Gynecol, 46, 26-32.
  15. Minaguchi T, Yoshikawa H, Oda K, et al (2001). PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas. Clinical Cancer Res, 7, 2636-42.
  16. Myatt SS, Wang J, Monteiro LJ, et al (2010) Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res, 70, 67-377.
  17. Okuda T, Sekizawa A, Purwosunu Y, et al (2010). Genetics of endometrial cancers. Obstet Gynecol Internl, 2010.
  18. Ortega-Molina A, Serrano M (2013). PTEN in cancer, metabolism, and aging. Trends Endocrinol Meta, 24, 184-9.
  19. Prat J, Gallardo A, Cuatrecasas M, Catasus L (2007). Endometrial carcinoma: pathology and genetics. Pathol, 39, 72-87.
  20. Risinger JI, Hayes AK, Berchuck A, Barrett JC (1997). PTEN/MMAC1 mutations in endometrial cancers. Cancer Res, 57, 4736-8.
  21. Risinger JI, Hayes K, Maxwell GL, Carney ME, Dodge RK, Barrett JC, Berchuck A (1998). PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res, 4, 3005-10.
  22. Seeber L, Zweemer RP, Verheijen RH, van Diest PJ (2010). Hypoxia-inducible factor-1 as a therapeutic target in endometrial cancer management. Obstet Gynecol Internl, 2010.
  23. Smuc T, Rupreht R, Sinkovec J, Adamski J, Rizner TL (2006). Expression analysis of estrogen-metabolizing enzymes in human endometrial cancer. Mol Cell Endocrinol, 248, 114-7.
  24. Sun H, Enomoto T, Fujita M, et al (2001). Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. Am J Clin Pathol, 115, 32-8.
  25. Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, et al (2010). Endometrial cancer in Thai women: clinicopathological presentation and survival. Asian Pac J Cancer Prev, 11, 1267-72.
  26. Tashiro H, Blazes MS, Wu R, et al (1997). Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res, 57, 3935-40.
  27. Thanapprapasr D, Thanapprapasr K (2013). Molecular therapy as a future strategy in endometrial cancer. Asian Pac J Cancer Prev, 14, 3419-23.
  28. Voss MA, Ganesan R, Ludeman L, et al (2012). Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation. Gynecol Oncol, 124, 15-20.
  29. Wang H-L, Liu M-M, Ma X, et al (2014). Expression and effects of JMJD2A histone demethylase in endometrial carcinoma. Asian Pac J Cancer Prev, 15, 3051.
  30. Zhao T, Lv J, Zhao J, Nzekebaloudou M (2009). Hypoxiainducible factor-$1{\alpha}$ gene polymorphisms and cancer risk: a meta-analysis. J Exp Clin Cancer Res, 28, 159.
  31. Zhu X-L, Ai Z-H, Wang J, et al (2012). Weighted gene coexpression network analysis in identification of endometrial cancer prognosis markers. Asian Pac J Cancer Prev, 13, 4607-11.

Cited by

  1. Vicenin-2 acts as a radiosensitizer of the non-small cell lung cancer by lowering Akt expression pp.09516433, 2018,